DNA — Ginkgo Bioworks Holdings Share Price
0.000.00%
Last trade - 00:00- $455.56m
- -$105.67m
- $227.04m
- 54
- 45
- 29
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.64 | ||
| Price to Tang. Book | 0.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -46.26% | ||
| Return on Equity | -60.34% | ||
| Operating Margin | -258.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 76.66 | 313.84 | 477.71 | 251.46 | 227.04 | 173.04 | 202.01 | 33.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 15th, 2021
- Public Since
- April 19th, 2021
- No. of Shareholders
- 624
- No. of Employees
- 834
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 58,033,600
- Address
- 27 Drydock Avenue, 8Th Floor, BOSTON, 02210
- Web
- https://investors.ginkgobioworks.com/
- Phone
- +1 3102097280
- Auditors
- Ernst & Young LLP
Upcoming Events for DNA
Similar to DNA
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Aurion Biotech
New York Stock Exchange
FAQ
What is the Ginkgo Bioworks Holdings share price?
As of Today at 20:49 UTC, shares in Ginkgo Bioworks Holdings are trading at $7.85. This share price information is delayed by 15 minutes.
How has the Ginkgo Bioworks Holdings share price performed this year?
Shares in Ginkgo Bioworks Holdings last closed at $7.85 and the price had moved by -77.48% over the past 365 days. In terms of relative price strength the Ginkgo Bioworks Holdings share price has underperformed the S&P500 Index by -78.83% over the past year.
What are the analyst and broker recommendations for Ginkgo Bioworks Holdings?
The overall consensus recommendation for Ginkgo Bioworks Holdings is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ginkgo Bioworks Holdings dividend yield?
Ginkgo Bioworks Holdings does not currently pay a dividend.
Does Ginkgo Bioworks Holdings pay a dividend?
Ginkgo Bioworks Holdings does not currently pay a dividend.
When does Ginkgo Bioworks Holdings next pay dividends?
Ginkgo Bioworks Holdings does not currently pay a dividend.
How do I buy Ginkgo Bioworks Holdings shares?
To buy shares in Ginkgo Bioworks Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ginkgo Bioworks Holdings?
As of the previous close price of $7.85, shares in Ginkgo Bioworks Holdings had a market capitalisation of $455.56m.
Where are Ginkgo Bioworks Holdings shares listed?
Here are the trading details for Ginkgo Bioworks Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: DNA
What kind of share is Ginkgo Bioworks Holdings?
Based on an overall assessment of its quality, value and momentum Ginkgo Bioworks Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ginkgo Bioworks Holdings share price forecast for 2025?
The analyst consensus target price for shares in Ginkgo Bioworks Holdings is $8.30. That is 5.73% above the last closing price of $7.85.
Analysts covering Ginkgo Bioworks Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$6.13 for the next financial year.
Find out moreWhat is the trend in the Ginkgo Bioworks Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ginkgo Bioworks Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -2.04%.
As of the last closing price of $7.85, shares in Ginkgo Bioworks Holdings were trading -16.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ginkgo Bioworks Holdings PE Ratio?
The Ginkgo Bioworks Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ginkgo Bioworks Holdings?
We do not have data on Ginkgo Bioworks Holdings' directors